Trial · NCT03517618
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
NCT03517618, Phase 2, Completed, TTY Biopharm
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC. Trials, record NCT03517618. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03517618
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
- NCT number
- NCT03517618
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 41 participants, actual
- Lead sponsor
- TTY Biopharm
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- S-1+leucovorin
- First posted
- 2018-05-07
- Last updated
- 2018-05-07
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Control Rate (DCR) | 6 months(an expected average) | Documented objective response (OR) (defined as partial response \[PR\] or complete response \[CR\]), assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment |
| Secondary | Objective Response Rate (ORR) | 6 months(an expected average) | the rate of completely response \[CR\] and partial response \[PR\] patients according to RECIST version 1.1. criteria |
| Secondary | Time to Progression (TTP) | until disease progression, intolerable toxicity, 12 months(an expected average) | Participants follow-up for disease progression occur. Maximum follow-up time is 12 months after the initial administration of the last subject |
| Secondary | Overall survival (OS) | at death or at the end of study, 24 months(an expected average) | median time between the start date of study treatment and the date of the death |
| Secondary | Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability] | From the date of study entry until 30 days after the last dose of study treatment | assessed by the NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0 and within some subgroups of patients |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03517618
GET https://conductscience.org/api/trials/v1/NCT03517618/papers?page=2